Ventyx Biosciences, Inc. logo

Ventyx Biosciences, Inc. (VTYX) Financials

NASDAQ NASDAQ:VTYX

Market Cap

2.21B

Total Revenue

--

Gross Profit

--

Operating Income

-113.14M

Net Income

-107.96M

Metric2019202020212022
--------
--------
--------
3,552,0006,366,00058,481,00087,738,000
--------
628,000684,0008,666,00025,398,000
628,000684,0008,666,00025,398,000
4,180,0007,050,00067,147,000113,136,000
-4,180,000-7,050,000-67,147,000-113,136,000
-147,000-21,124,000-16,599,0004,710,000
-4,181,000-7,051,000-72,596,000-108,426,000
-1,000-1,000-5,449,0004,710,000
------4,669,000
146,000358,00099,000-4,710,000
-4,327,000-28,174,000-83,746,000-108,426,000
146,000358,000-5,380,000-470,000
-4,473,000-28,532,000-78,366,000-107,956,000
-2.25-1.35-6.11-2.06
-2.25-1.35-6.11-2.06
1,988,58521,120,08912,825,59852,471,003
1,988,58521,120,08912,825,59852,471,003
4,180,0007,050,00067,147,000113,136,000
-1,000-1,000-5,449,00041,000

Key Facts

Industry

Biotechnology

Sector

Healthcare

Headquarters

Encinitas, CA, US

CEO

Dr. Raju S. Mohan Ph.D.

Employees

91

About the Company

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.